



Zycortal®

A prolonged-release suspension used as replacement therapy for mineralocorticoid deficiency in dogs with primary hypoadrenocorticism

Zycortal® is the only veterinary-licensed product in New Zealand for the treatment of canine Addison's disease.

Zycortal® contains desoxycortone pivalate (DOCP), which is a pure mineralocorticoid hormone that regulates electrolytes and water balance, which are impaired in cases of mineralocorticoid deficiency in Addison's disease. Unlike some other mineralocorticoids, DOCP has limited glucocorticoid activity, allowing the independent dose titration of mineralocorticoid without the risk of inducing marked side effects from glucocorticoid oversupplementation eg polyuria, polydipsia, polyphagia and muscle atrophy.

Addison's disease, potentially life-threatening, resembles many other illnesses so it can be challenging to diagnose. Being more aware of this condition is half the battle. For a wealth of information on this disease, please visit our website.

ACVM Registration No: 11422

Product Features

- Presented in a 4ml vial.
- Contains DOCP which controls serum electrolytes more effectively than fludrocortisone.
- Long term administration allows for the long-term control of primary Addison's disease.
- Highly efficacious in controlling Addison's disease with clinical success rates >80%.
- Lasts for 120 days once opened.

What dose to use?

- Initial dosage is 2.2 mg/kg body weight administered by subcutaneous injection, repeated in 25 days.
- Dose and/or treatment interval may need to be varied based on individual clinical response.

For more information please contact your Veterinary Account Manager or RXVET Technical Support Line on 0800 4 RXVET (79838)